Rachel Mendenhall, PA
Medical · Ashland, OHNPI 1760760185
Payments from drug & device makers
Across 108 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$308
- AstraZeneca$141
- Johnson & Johnson$119
- Boehringer Ingelheim$117
- Neurocrine Biosciences, Inc.$117
- Otsuka America Pharmaceutical, Inc.$112
- plus $942 from 26 others
What the payments were for
- Food & beverage$1,855100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 19 | $308 |
| AstraZeneca | 8 | $141 |
| Johnson & Johnson | 7 | $119 |
| Boehringer Ingelheim | 7 | $117 |
| Neurocrine Biosciences, Inc. | 6 | $117 |
| Otsuka America Pharmaceutical, Inc. | 6 | $112 |
| GSK | 6 | $95 |
| Nestle Healthcare Nutrition Inc. | 5 | $79 |
| Teva Pharmaceuticals USA, Inc. | 4 | $72 |
| Exact Sciences | 3 | $64 |
| Lundbeck LLC | 3 | $50 |
| Bayer | 3 | $49 |
| Pfizer | 3 | $47 |
| Amgen | 3 | $47 |
| Aimmune Therapeutics, Inc. | 2 | $40 |
| Novartis | 2 | $40 |
| Amneal Pharmaceuticals LLC | 2 | $37 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| Lilly USA, LLC | 2 | $33 |
| Mylan Specialty L.p. | 2 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Braintree Laboratories, Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Acadia Pharmaceuticals Inc | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| Upsher-smith Laboratories LLC | 1 | $16 |
| Ardelyx, Inc. | 1 | $15 |
| Abbott | 1 | $15 |
| Athena Bioscience, LLC | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$1,855 in reported general payments places this provider in the 75th percentile of 547 medical providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 177 | $192,141 |
| TrulicityDulaglutide | 33 | $39,596 |
| TradjentaLinagliptin | 33 | $35,333 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $29,660 |
| JardianceEmpagliflozin | 20 | $27,258 |
| EliquisApixaban | 18 | $26,835 |
| JanuviaSitagliptin Phosphate | 29 | $26,590 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 40 | $18,296 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 76 | $16,091 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 31 | $15,788 |
| FarxigaDapagliflozin Propanediol | 12 | $14,819 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $12,893 |
| Fluticasone Propionate HfaFluticasone Propionate | 25 | $11,104 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $9,638 |
| XareltoRivaroxaban | 12 | $8,890 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $17 | $192,141177 claims |
| Boehringer IngelheimTradjenta, Jardiance | $117 | $62,59153 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $95 | $57,59496 claims |
| Lilly USA, LLCTrulicity | $33 | $39,59633 claims |
| AstraZenecaBevespi Aerosphere, Farxiga | $141 | $30,60743 claims |
| PfizerEliquis | $47 | $26,83518 claims |
| AbbVieLinzess, Synthroid, Armour Thyroid | $308 | $9,72146 claims |
| Johnson & JohnsonXarelto | $119 | $8,89012 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $37 | $2,435273 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 547 medical providers in Ohio.
Other medical in Ashland
- Shannon GhizzoniColumbus$116K
- Susan WhittCanal Winchester$74K
- Christopher FrickLima$46K
- Kodi VealeAkron$43K
- Abbey BlairCleveland$24K
- Joana ZulaConcord Twp$23K
- Chelsea AustenColumbus$21K
- Kristen FairchildToledo$19K
- Kaitlin SchuppGahanna$17K
- Melanie HunglerCincinnati$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.